Palatin CEO claims ‘a positive study on its face,’ despite dry eye drug's primary...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 28, 2024 at 10:52: AM
via Palatin Technologies has some changes to make for the upcoming trials of the dry eye disease drug PL9643 after the phase 3 MELODY-1 study failed on the main goal of improving a clinical sign of the disorder.

article source
 

<



Similar threads

cafead
Palatin Technologies commences Phase II study of obesity treatment
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Palatin sells female libido drug Vyleesi to Cosette for $12M, plus more in potential milestones
Replies
0
Views
110
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Palatin enrols first subject in Phase II ulcerative colitis therapy trial
Replies
0
Views
125
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
Replies
0
Views
8
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
23andMe independent directors quit board over unsatisfactory buyout plan from CEO
Replies
0
Views
24
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote